B
Barbara Bohle
Researcher at Medical University of Vienna
Publications - 224
Citations - 10458
Barbara Bohle is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Epitope & T cell. The author has an hindex of 53, co-authored 210 publications receiving 9413 citations. Previous affiliations of Barbara Bohle include University of Vienna & Johannes Kepler University of Linz.
Papers
More filters
Journal ArticleDOI
EAACI Molecular Allergology User's Guide.
Paolo Maria Matricardi,Jörg Kleine-Tebbe,Hans Jürgen Hoffmann,Rudolf Valenta,Christiane Hilger,Stephanie Hofmaier,Rob C. Aalberse,Ioana Agache,Riccardo Asero,Barbara Ballmer-Weber,Domingo Barber,Kirsten Beyer,Tilo Biedermann,M. B. Bilò,Simon Blank,Barbara Bohle,Philipp P. Bosshard,Heimo Breiteneder,Helen A. Brough,Luis Caraballo,J-C Caubet,Reto Crameri,Janet M. Davies,Nikolaos Douladiris,M. Ebisawa,Philippe Eigenmann,Montserrat Fernandez-Rivas,Fatima Ferreira,Gabriele Gadermaier,Martin Glatz,Robert G. Hamilton,Thomas Hawranek,P W Hellings,Karin Hoffmann-Sommergruber,Thilo Jakob,Uta Jappe,Marek Jutel,Sandip D. Kamath,Edward F. Knol,Peter Korošec,Annette Kuehn,Gideon Lack,Gideon Lack,Andreas L. Lopata,Mika J. Mäkelä,Martine Morisset,Verena Niederberger,Anna Nowak-Wegrzyn,Nikolaos G. Papadopoulos,Elide A. Pastorello,Gabrielle Pauli,Thomas A.E. Platts-Mills,Daniela Posa,Lars K. Poulsen,Monika Raulf,Joaquín Sastre,Enrico Scala,Johannes Schmid,Peter Schmid-Grendelmeier,M. van Hage,R. van Ree,Stefan Vieths,Richard W. Weber,Magnus Wickman,Antonella Muraro,Markus Ollert +65 more
TL;DR: The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) as mentioned in this paper provides comprehensive information on important allergens and describes the diagnostic options using component-resolved diagnosis (CRD).
Journal ArticleDOI
Sublingual immunotherapy induces IL-10–producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation
Barbara Bohle,Tamar Kinaciyan,Marianne Gerstmayr,Astrid Radakovics,Beatrice Jahn-Schmid,Christof Ebner +5 more
TL;DR: SLIT induces regulatory T-cell suppression through IL-10 during the early phase and specific nonreactivity and immune deviation of allergen-specific T cells during the later phase of therapy.
Journal ArticleDOI
Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen.
C. Ebner,Ute Siemann,Barbara Bohle,Martin Willheim,Ursula Wiedermann,Siegfried Schenk,F. Klotz,H. Ebner,Dietrich Kraft,Otto Scheiner +9 more
TL;DR: This study evaluated immunological changes during SIT in pollinosis with a focus on type I allergy and found thatType I allergy patients are more likely to benefit from SIT treatment.
Journal ArticleDOI
Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods.
Montserrat Fernandez-Rivas,S.T.H.P. Bolhaar,Eloína González-Mancebo,Riccardo Asero,Astrid van Leeuwen,Barbara Bohle,Yan Ma,Christof Ebner,Neil M. Rigby,Ana I. Sancho,Susan Miles,Laurian Zuidmeer,André C. Knulst,Heimo Breiteneder,Clare Mills,Karin Hoffmann-Sommergruber,Ronald van Ree +16 more
TL;DR: The analysis of individual apple allergens in a clinical context has provided insight into the sensitization pathway and into the intrinsic risk an allergen bears to induce mild or severe food allergy.
Journal ArticleDOI
Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper
Mohamed H. Shamji,Mohamed H. Shamji,Jasper H. Kappen,M. Akdis,Erika Jensen-Jarolim,Erika Jensen-Jarolim,Edward F. Knol,Jörg Kleine-Tebbe,Barbara Bohle,Adam Chaker,Stephen J. Till,Stephen J. Till,Rudolf Valenta,Lars K. Poulsen,Moises A. Calderon,Moises A. Calderon,Pascal Demoly,Oliver Pfaar,Lars Jacobsen,Stephen R. Durham,Stephen R. Durham,Carsten B. Schmidt-Weber +21 more
TL;DR: Clinical management of patients receiving AIT and efficacy in randomised controlled trials for drug development could be enhanced by predictive biomarkers that are predictive of the clinical response to AIT.